Clinical Trials Logo

Acute GVHD clinical trials

View clinical trials related to Acute GVHD.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04645667 Completed - Acute GVHD Clinical Trials

Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Start date: February 1, 2021
Phase:
Study type: Observational

The purpose of this research study is to evaluate tacrolimus plasma concentrations in patients who will undergo an allogeneic hematopoietic stem cell transplant (HCT). The study aims to identify associations between plasma concentrations, baseline demographic characteristics, clinical lab parameters, and genetic factors. These associations will help clinicians determine the best starting dose for tacrolimus in order to minimize risks of aGVHD and tacrolimus-induced toxicities.

NCT ID: NCT02806947 Completed - Acute GVHD Clinical Trials

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The study is a Phase II randomized, open label, multicenter trial designed to identify whether sirolimus is a potential alternative to prednisone as an up-front treatment for patients with standard-risk acute GVHD defined according to clinical and biomarker-based risk stratification. This trial incorporates both a novel up front GVHD therapy (sirolimus) as well as a novel BMT CTN developed acute GVHD biomarker test.

NCT ID: NCT02631993 Completed - AML Clinical Trials

Photochemotherapy and Graft-versus-leukemia in Acute-leukemia

Start date: October 2014
Phase: N/A
Study type: Observational

Cure of leukemia after hematopoietic stem cell transplantation (HSCT) is sustained by the anti-leukemic effect of the grafted cells (graft-versus-leukemia (GVL)). However, it is not known whether the tumor-immunity is affected by photochemotherapy (psoralene photosensitization and ultraviolet light radiation) administered to attenuate graft-versus host disease (GVHD). The present study aim to investigate what happens to the GVL after photochemotherapy of aGVHD in a predominantly retrospective setting with 10-years follow-up after HSCT

NCT ID: NCT00350181 Completed - Leukemia Clinical Trials

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Start date: August 2006
Phase: Phase 2
Study type: Interventional

GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL